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Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to
attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven
leukemogenesis in a patient with multiple TET2 mutations and JAK2 V617F mutated chronic myelopro-
liferative neoplasm. The del(7q) emerged in the accelerated phase of disease, which was preceded by a
lag phase of almost three years with normalized peripheral blood cell counts. Our results reveal that the
del(7q), independently of other lesions, acts as a leukemic driver in this patient and that the stable long-
lasting normalization of peripheral blood cell values concealed pending transformation.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
The chronic myeloproliferative neoplasms (MPN) comprise a
group of clonal stem cell disorders with a high prevalence of the
JAK2 V617F mutation (JAK2+) causing excessive production of
mature blood cells. Transformation to acute myeloid leukemia
(AML) is seen in 2–5% of patients with polycythemia vera and
essential thrombocythemia (ET), and in 15–30% with primary
myeloﬁbrosis [1]. Overt AML in these cases is usually preceded by
an accelerated phase of disease characterized by deranged hema-
topoiesis [2]. The JAK2+ aberration by itself is not sufﬁcient to cause
blastic transformation but induces genomic instability, which may
predispose to leukemic transformation. Additionally, other muta-
tions have been described in this setting although it remains
uncertain to what extent they contribute to disease progression
[3]. TET2, a member of the ten-eleven-translocation family of genes,
is mutated in 7–13% of all MPN cases, but less frequently so in ET
[4]. Mutated TET2 has been suggested to found a pre-MPN clone
while other data suggest it to be a late event in the progression of
MPN [5,6]. As in AML, speciﬁc cytogenetic aberrations in MPN
hold prognostic potential. Such aberrations tend to accumulate and
up to 95% of the patients have an abnormal karyotype in theAarhus University Hospital,
enmark. Tel.: +45 78467584;
-NC-ND license.transformation phase [7]. Despite the obvious clinical importance of
AML development in MPN patients, the causative genetic mechan-
isms and clinical development are poorly understood. We here
report a case of JAK2+ ET with multiple TET2 mutations that
progressed to del(7q) positive AML after an almost three years lag
phase prominent by normalized blood cell counts.
In February 2009 a 64-yr-old woman presented with peripheral
thrombosis. The platelet count was 1263109/L, total leukocytes
14.4109/L, hemoglobin 9.4 mmol/L and hematocrit 0.45. Abdom-
inal ultrasound did not reveal splenomegaly. The JAK2 allele
burden was 14%. Morphology was consistent with ET with triline-
age hyperplasia dominated by excess of large, hyperlobulated and
loosely clustered mekaryocytes. The iron content was normal and
there was no reticulin ﬁbrosis. Standard G-Banding revealed a
normal karyotype. She was diagnosed with ET and was subse-
quently treated with hydroxyurea and low dose aspirin (Fig. 1).
Therapy was discontinued due to cytopenias in June 2009. Despite
withdrawal of cytoreductive treatment, peripheral blood cell
counts stayed normal (Fig. 1). A routine check in February 2012
revealed leukocytosis of 129109/L with neutrocytosis of
98109/L, hemoglobin 5.7 mmol/L, and platelets 214109/L. The
JAK2+ allele burden had declined to 0.2% (Fig. 1). Morphology and
ﬂow cytometry did not disclose blastic transformation (Fig. 2A and B).
Now standard G-Band karyotyping revealed a del(7q) in 21/25
metaphases (Fig. 2D). The patient was deemed in accelerated
phase of MPN with high risk of transformation and was offered
cytoreduction with 2 days of anthracycline and 5 days of cytarabine,
Fig. 1. Longitudinal tabulation of key laboratory parameters during the course of disease.
Fig. 2. Morphology, ﬂow cytometry, cytogenetic, and TET2 mutation analyses of bone marrow from the acceleration phase. (A) Hematoxylin and Eosin (HE) stained bone
marrow from different phases of the disease. 1: ET diagnosis with an excess of megakaryocytes and left-shifted granulopoiesis without excess blasts. 2: During the
accelerated phase, differentiated myelopoiesis still dominates with slight increase in myeloblasts not exceeding 5%, loosely clustered megakaryocytes, and grade 1 reticulin
ﬁbrosis. 3: After transformation to AML immature myeloid cells dominate. (B). Multicolor ﬂow cytometry at early acceleration showing 0.7% immature CD34+CD117+cells.
(C) TET2 mutation sequencing. 1 and 2: Loss-of-function mutations 3: Missense variant (not previously reported). All TET2 mutations were present at the time of diagnosis of
ET and remained during progression of disease. Mutations are annotated according to TET2 sequence ENST00000380013. (D) Standard G-band karyotyping and genomic
proﬁling of chromosome 7 from bone marrow cells from the acceleration phase. 1: Karyogram displaying del(7q) 2: Ideogram revealing a deletion in region 7q22.1-q35 as
indicated by red shading 3: Conﬁrmatory FISH with probes ELN (red) and D7S486/D7S522 (green). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Unfortunately, she progressed during treatment and was diagnosed
with AML in May 2012 and succumbed to this in January 2013. The
almost three year long lag phase with stable normalized peripheral
blood cell counts preceding the acceleration phase, led us to further
delineate the pathogenetic mechanisms by analyzing bone marrow
(BM) cells from critical time points.
At the time of initial diagnosis as well as during progression
and in the AML phase, the patient was negative for mutations in
CEBPa, FLT3-ITD, FLT3-D835, cKIT D816V, IDH1 R132, NPM1, and
WT1 exon 7 indels as analyzed by a sensitive multiplex
ﬂuorescent-labeled capillary gel electrophoresis. In addition, she
was negative for balanced reciprocal AML- and CML-related
translocations by standard qPCR and FISH and negative for gene
rearrangements of PDGFRA and PDGFRB. TET2 mutation screening,
by a combination of denaturing gradient gel electrophoresis and
Sanger sequencing of the entire coding sequence and splice sites,
disclosed two loss-of-function mutations (c.2601 del T and c.3810-
3811 INS C) as well as a previously unreported TET2 missense
mutation (c.A1505T) in all samples from ET diagnosis, accelerated
phase, and AML (Fig. 2C).
To more accurately map the del(7q) and to search for other
submicroscopic aberrations, we performed BAC-based array CGH
analysis on BM from the accelerated phase. This conﬁrmed an
interstitial deletion in chromosome bands 7q22.1-q35 of maximal
size 50.0 Mb (Fig. 2D). The minimal region of deletion encom-
passed BAC-probes RP11-494L11 to RP5-819O4 mapping from
98,055,374 bp to 144,989,208 bp and the maximal region with
BAC-probes RP5-1145A22 to RP11-302C22 mapping from
97,163,382 bp to 147,171,825 bp. There were no additional copy
number changes. Conﬁrmatory interphase nuclei FISH analysis
was positive in 91% of the BM cells (Fig. 2D). Retrospective FISH
analysis of BM from the time of ET diagnosis was negative for del
(7q) (0/1000 cells counted). Finally, we quantiﬁed the load of del
(7q) by FISH on FACS-sorted stem and progenitor cells in the
acceleration phase. We found 39% del(7q) positive cells in the stem
cell containing compartment (CD34+CD38−) and 78% of com-
mitted myeloid progenitors (CD34+CD38+) were positive.
Our patient highlights several important features of disease
progression of MPN. Foremost, the del(7q) represents a key event
in this patient. While the leukemogenic potential and the poor
prognosis associated with this aberration are described, little is
known about associated molecular changes and the kinetics of
disease progression [7,8]. The almost three years long lag phase was
characterized by a stable normalization of blood cell counts and a
signiﬁcant decrease in JAK2+ allele burden. Although JAK2+ does
not affect survival or leukemic transformation, signiﬁcant changes
in the allele burden can be a harbinger of transformation [9].
While retrospective FISH analysis of BM from ET diagnosis was
negative for the del(7q), the exact time for acquisition of this
aberration remains speculative. The remarkable long-lasting period
with normalized peripheral blood cell values after cessation of
cytoreductive therapy, may be the result of a slow and gradual
displacement of the MPN clone and residual normal hematopoiesis
by the del(7q) clone. Considering the del(7q) in relation to the JAK2
and TET2 mutations, we did not obtain enough cells for molecular
analysis of sorted subpopulations. However, the JAK2 and the del
(7q) most likely occurred in two independent stem cells that
already harbored all three TET2 mutations. This is reﬂected by the
fact that the del(7q) was present in 91% of analyzed cells from the
acceleration phase whereas the JAK2+ was quantiﬁed only at the
0.2% level. The stable TET2 mutational status from ET to overt AML
indicates that loss of TET2 function was not implicated in disease
progression in this case but rather represents an early priming
event in the hematopoietic progenitors. Presence of multiple TET2mutations, two loss-of-function and one missense variant, has not
been described previously in ET patients [4]. The A1505T might be a
rare normal germline variant, but involved tissue was not available
for conﬁrmation of this. Needless to say, more patients are needed
to evaluate whether the rare cases of ET transformation, could
harbor similar complex TET2 mutations and to address the possible
clonal heterogeneity [10].
It might be speculated if the patient had an early preﬁbrotic
stage of myeloﬁbrosis at the time of initial diagnosis, which per se
implies an increased risk of myeloﬁbrotic and leukemogenic
transformation [11]. However, there was no strong evidence of
this in the bone marrow biopsies. Additionally, this does not
diminish the important information obtained in the patient
regarding the malignant progression described.
In conclusion, AML transformation in the reported patient was
driven by the del(7q) and preceded by a notable lag phase of three
years of sustained normalization of peripheral blood cell counts,
which may have concealed pending transformation. The del(7q)
most likely emerged in a JAK2 wild type clone and the disease
progression appeared uninﬂuenced by an otherwise complex but
stable TET2 mutational status.Contribution
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